Contrive Datum Insights has published "Human Microbiome Market Size, Share & Industry Analysis, By Product type (Probiotics, Prebiotics, Medical Foods, Supplements, Others), Application (Therapeutics, Diagnostics), Disease (Metabolic and Gastrointestinal Disorders, Obesity, Diabetes, Autoimmune Disorder, Cancer, Other Diseases), Technology (Sequencing, Spectrometry, Genomics and Bioinformatics Tools, Other Technologies), End user (Hospitals and Diagnostic Centers, Research and Academic Institutes, Homecare and Retail), and Regional Forecast, 2026-2034". The study sizes the global human microbiome market at USD 1190 million in 2025 and projects growth from USD 1404.2 million in 2026 to USD 5461.8 million by 2034, a compound annual growth rate of 18.51% across the forecast period.
The human microbiome market covers products and technologies built around the community of bacteria, viruses and fungi that live in and on the human body, most concentrated in the gastrointestinal tract. It spans live biotherapeutic and prebiotic formulations designed to restore or support a healthy microbial balance, diagnostic tests that sequence or profile a patient's microbial makeup, and consumer probiotic and prebiotic supplements sold for general digestive and immune wellness. Buyers range from pharmaceutical and biotechnology developers pursuing clinical indications, to hospitals and diagnostic laboratories running microbiome-based tests, to individual consumers purchasing over-the-counter probiotic products.
Rising prevalence of chronic metabolic and gastrointestinal disorders
Rising prevalence of chronic metabolic and gastrointestinal disorders is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 18.51% a year, the product type lines exposed to it move fastest: Supplements compounds at 20.19%, taking its share of revenue from 22% to 25% and its value from USD 261.8 million to USD 1365.45 million.
On the upside, the study's bull case assumes bull case assumes at least two live biotherapeutic candidates reach commercial approval before 2030 and consumer probiotic demand continues to outpace general food and supplement category growth, which would take 2034 revenue to USD 5953.36 million against the USD 5461.8 million base case.
The downside is specific. Bear case assumes continued regulatory delay for live biotherapeutic approvals through the forecast period and a slowdown in consumer supplement spending growth back toward general category rates, and 2034 revenue lands at USD 4970.24 million. Probiotics is the drag, 38% of the 2025 base compounding at 17.43% while the market runs at 18.51%.
Probiotics Scale Against Supplements Momentum
Two positions matter, and they are set by product type. Probiotics carries 38% of 2025 revenue (USD 452.2 million) and is still the largest line in 2034 at 35%, hard to take from an incumbent. Supplements, at 20.19%, is where the USD 1190 million base is redistributed. The two demand different capabilities.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product type | Probiotics | 38% · USD 452.2 million | — |
| Application | Therapeutics | 65% · USD 773.5 million | Diagnostics 19.54% |
| Disease | Metabolic and Gastrointestinal Disorders | 32% · USD 380.8 million | Cancer 22.3% |
| Technology | Sequencing | 48% · USD 571.2 million | Genomics and Bioinformatics Tools 20.68% |
| End user | Hospitals and Diagnostic Centers | 40% · USD 476 million | Homecare and Retail 20.88% |
- North America was the largest region in 2025, holding 42% of global revenue at USD 499.8 million and reaching USD 2075.48 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22% in 2025 to 28% in 2034, with revenue growing from USD 261.8 million to USD 1529.3 million.
- Middle East and Africa stays the smallest contributor across the period: 4% of revenue in 2025 and 4% in 2034.
- No product type line grows faster than Supplements, at a projected 20.19%.
- The United States is the largest single country market at USD 409.84 million in 2025, 34.44% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by product type, and by application, disease, technology and end user. The headline total carries bear, base and bull cases at USD 4970.24 million and USD 5953.36 million by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.